Essential digital access to quality FT journalism on any device. Pay a year upfront and save 20%.
Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.
，更多细节参见heLLoword翻译官方下载
ARPL Architects
stack2.pop(); // 弹出无效的候选值